Beacon Capital Management, LLC Galectin Therapeutics Inc Transaction History
Beacon Capital Management, LLC
- $580 Million
- Q3 2024
A detailed history of Beacon Capital Management, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Beacon Capital Management, LLC holds 23,905 shares of GALT stock, worth $49,483. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,905
Previous 23,905
-0.0%
Holding current value
$49,483
Previous $54,000
20.37%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding GALT
# of Institutions
91Shares Held
9.65MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$4.42 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$3.24 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$2.45 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$1.79 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $123M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...